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Summary
Background.  —  Several  studies  have  shown  gender  differences  in  the  management  of  cardiovas-
cular risk  factors  and  diseases.  Whether  the  management  of  hypertension  by  cardiologists  in
France differs  according  to  patient  gender  has  not  been  fully  investigated.
Aims. —  The  main  objective  of  this  cross-sectional,  multicentre  study  was  to  examine  the  mana-r  of  hypertensive  patients  by  ofﬁce-based  cardiologists  in  France.risk; gement according  to  gende
Hypertension;
Women
Methods.  —  Cardiologists  were  asked  to  include  consecutively  two  men  and  two  women
attending  a  routine  consultation  for  essential  hypertension.  Therapeutic  management
was evaluated  by  comparing  cardiovascular  investigations  in  the  preceding  6  months  and
hypertension  control  according  to  gender  and  the  patients’  global  cardiovascular  risk.
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; CVRF, cardiovascular risk factor; DBP, diastolic blood pressure;
GCVR, global cardiovascular risk; SBP, systolic blood pressure.
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Results.  —  Overall,  data  from  3440  adult  patients  (53%  men)  referred  to  654  cardiologists  were
analysed.  Hypertension  was  uncontrolled  in  76%  of  both  men  and  women  and  69%  were  at  high
global cardiovascular  risk  (75%  of  men,  62%  of  women;  P  <  0.001).  Signiﬁcantly  fewer  cardiovas-
cular investigations  had  been  performed  in  the  preceding  6  months  in  women  (22.6%  vs  44.2%
in men;  P  <  0.001).  The  treatment  regimen  was  changed  by  the  cardiologist  in  approximately
50% of  patients  regardless  of  gender  or  global  cardiovascular  risk.
Conclusions.  —  The  PARITE  study  shows  that  in  French  ofﬁce-based  cardiology  practice,  the
antihypertensive  regimen  is  adjusted  as  often  in  female  as  in  male  patients.  However,  the
results suggest  that  there  is  room  for  improvement  in  the  investigation  of  cardiovascular  disease
in women.  Healthcare  providers  could  be  encouraged  to  implement  established  guidelines  on
the prevention  of  cardiovascular  disease  in  women.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  Le  risque  cardiovasculaire  est  généralement  sous-estimé  chez  la  femme.  La
maladie cardiovasculaire  peut  se  manifester  différemment  et  nécessiter  des  stratégies
thérapeutiques  différentes  chez  l’homme  et  la  femme.
Objectifs.  —  L’objectif  principal  de  cette  étude  franc¸aise  observationnelle,  transversale,  multi-
centrique,  a  été  d’évaluer  en  fonction  du  sexe,  la  prise  en  charge  par  des  cardiologues  libéraux
de l’hypertension  artérielle  (HTA)  et  du  risque  cardiovasculaire  global.
Méthodes.  —  Les  cardiologues  devaient  inclure  les  deux  premiers  hommes  et  les  deux  pre-
mières femmes  vus  en  consultation  de  routine  pour  une  hypertension  essentielle.  La  prise  en
charge était  analysée  en  termes  de  décision  thérapeutique  à  la  ﬁn  de  la  visite,  en  fonction  du
sexe, du  risque  cardiovasculaire  (CV)  global  et  du  contrôle  de  l’hypertension.  Les  examens  CV
complémentaires  des  six  mois  précédents  étaient  également  analysés.
Résultats.  — Parmi  les  3440  patients  adultes  (53  %  hommes  et  47  %  femmes)  inclus  dans  cette
analyse par  654  cardiologues,  76  %  de  la  population  globale  de  l’étude,  ainsi  que  des  femmes
et des  hommes  avaient  une  HTA  non  contrôlée  et  69  %  un  risque  cardiovasculaire  global  élevé
(75 %  des  hommes,  62  %  de  femmes  ;  p  <  0,001).  Le  traitement  antihypertenseur  a  été  modiﬁé
de la  même  manière  dans  les  deux  sexes  pour  50  %  des  patients.  Enﬁn,  44,2  %  des  hommes  et
22,6 %  des  femmes  ont  bénéﬁcié  d’un  dépistage  de  l’ischémie  myocardique  (p  <  0,001).
Conclusions.  — L’étude  Parite  montre  qu’en  France,  dans  une  population  d’hypertendus  suivis
par des  cardiologues  libéraux,  l’adaptation  du  traitement  antihypertenseur  se  fait  de  manière
équivalente  entre  hommes  et  femmes,  et  reste  conditionnée  par  le  contrôle  tensionnel  et  ce
indépendamment  du  niveau  de  risque  cardiovasculaire  global.  Une  amélioration  de  la  prise  en
compte des  recommandations  spéciﬁques  dans  le  diagnostic  et  le  traitement  de  la  maladie
cardiovasculaire  chez  la  femme  reste  néanmoins  nécessaire  pour  une  prévention  efﬁcace.
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ackground
hile  there  is  a  popular  perception  that  women  are  less
usceptible  to  cardiovascular  disease  (CVD),  it  is  less  well
ecognized  that  this  is  no  longer  true  after  menopause:
n  Europe,  cardiovascular  mortality  is  in  fact  higher  in
omen  than  in  men  (55%  compared  with  43%)  [1].  However,
VD  presents  differently  in  men  and  women  [2]  and  there
s  evidence  that  treatment  efﬁcacy  is  different  between
enders;  for  example,  compared  with  male  patients,  aspirin
s  more  effective  in  female  patients  in  preventing  stroke  [3]
hereas  it  is  less  effective  in  preventing  myocardial  infarc-
ion  [4].  However,  it  has  been  shown  that  antihypertensive
reatment  can  be  as  effective  in  women  as  in  men  [5].  In
his  context,  the  Women  at  Heart  initiative  was  launched  by
he  European  Society  of  Cardiology  in  2005  to  highlight  the
rowing  burden  and  under-appreciation  of  heart  disease  in
omen  and  to  improve  the  management  of  women  at  risk
f  CVD  in  clinical  practice.  This  initiative  focused  on  the
p
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in  SAS.
valuation  of  cardiovascular  risk  factors  (CVRFs)  (especially
he  weighting  of  the  various  different  factors)  and  the
rescription  of  adapted  treatment  regimens  [4].  Conse-
uently,  the  newly  released  Proceedings  of  the  European
ociety  of  Cardiology  Workshop  on  Gender  Differences  in
VD  emphasized  the  need  to  implement  strategies  that
mprove  perspectives  in  women  [6,7].
The  percentage  of  patients  being  treated  for  hyperten-
ion  in  France  rose  from  19.6%  of  the  population  in  2000
o  22.8%  in  2006  [8].  It  has  been  conclusively  demonstrated
hat  lowering  high  blood  pressure  (BP)  by  drug  treatment
educes  the  incidence  of  fatal  and  non-fatal  cardiovascular
vents  [9,10]. However,  BP  is  just  one  of  the  major  factors
hat  affects  cardiovascular  risk  [11]. Therefore,  to  decide
n  the  therapeutic  approach  to  be  adopted  for  a  given
atient,  the  current  European  guidelines  recommend  taking
nto  account  not  only  BP  but  also  the  patient’s  global  cardio-
ascular  risk  (GCVR)  based  on  CVRFs,  end-organ  damage  and
ntercurrent  cardiovascular  or  renal  disease  [12]. Similarly,
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the  current  French  recommendations  promote  a  holistic
approach  in  which  more  aggressive  pursuit  of  BP  control  is
warranted  in  patients  at  higher  cardiovascular  risk  [13].
Barriers  to  effective  CVD  management  in  women  exist.
Among  these  barriers,  the  American  Heart  Association  has
identiﬁed  confusion  as  a  result  of  mixed  messages  from  the
media,  women  not  perceiving  themselves  to  be  at  risk  and
healthcare  providers  failing  to  inform  women  of  the  value
of  prevention  in  CVD  [14]. A  recent  report  of  the  EuroHeart
project  has  shown  that  women  are  still  under-represented  in
many  cardiovascular  clinical  trials  although  there  are  impor-
tant  gender  differences  in  most  areas  of  heart  disease  [7].
Very  little  is  known  about  how  French  cardiologists  man-
age  hypertension  in  the  ofﬁce  or  clinical  setting,  especially
with  respect  to  gender.  The  PARITE  study  was  organized  to
gain  insight  into  how  French  cardiologists  are  managing  male
and  female  hypertensive  patients  in  an  ofﬁce  setting.
Methods
In  this  cross-sectional,  observational,  French  multicen-
tre  study,  cardiologists  were  randomly  selected  from  a
geographically  stratiﬁed  database  (IDREM)  and  invited  to
participate  in  the  study.  Those  who  agreed  were  asked  to
include,  over  a  period  of  3  months,  the  ﬁrst  four  consecutive
patients  fulﬁlling  the  inclusion  criteria  (two  men  and  two
women,  in  no  stipulated  order).  The  patients  included  were
adult  outpatients  with  essential  hypertension  but  no  acute
condition,  attending  for  a  routine  consultation.  Patients
with  secondary  or  malignant  hypertension  and  pregnant
women  were  excluded.
The  primary  endpoint  was  the  therapeutic  decision
resulting  from  the  visit,  with  a  focus  on  changes  in  the
patient’s  treatment  regimen  according  to  both  gender  and
GCVR  status  as  deﬁned  by  the  French  Health  Authority
recommendations  [13].
CVD  management  was  deﬁned  as  the  therapeutic  deci-
sion  made  at  the  end  of  the  visit  coupled  with  an  analysis  of
the  complementary  cardiovascular  investigations  (echocar-
diography,  exercise  stress  testing,  coronary  angiogram  and
sleep  apnoea  test)  performed  within  the  previous  6  months.
CVD  management  was  assessed  in  the  patient  population
as  a  whole  and  broken  down  according  to  gender,  GCVR,  end-
organ  damage,  hypertension  control  and  geographic  region.
All  data  were  recorded  at  a  single  visit  on  the  basis  of
a  physical  examination,  the  patient’s  medical  records  and
an  interview.  Systolic  BP  (SBP)  and  diastolic  BP  (DBP)  were
measured  in  line  with  current  French  guidelines:  two  read-
ings  were  made  at  least  5  minutes  apart  with  the  patient
in  a  sitting  position  (after  a  rest  of  at  least  5  minutes);  the
result  recorded  was  the  mean  of  the  two  readings.  BP  con-
trol  was  deﬁned  as  BP  less  than  140/90  mmHg,  or  less  than
130/80  mmHg  if  the  patient  was  diabetic  or  had  impaired
kidney  function.
Data  were  acquired  on:  demographic  details;  body
weight  and  height;  medical  and  surgical  history;  family
history  of  premature  cardiovascular  events;  diabetes;  blood
lipid  levels;  smoking  status;  abdominal  obesity;  lifestyle;
alcohol  consumption;  end-organ  damage  (microalbuminuria
readings  and  left  ventricular  hypertrophy  as  measured  by
electrocardiography  and  echocardiography);  concomitant
o
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ardiovascular  and  kidney  disease;  and  any  additional
ardiovascular  tests  or  procedures  performed  within  6
onths  prior  to  the  study  visit.  Antihypertensive  treatment
etails  and  other  cardiovascular  drugs  were  recorded.  At
he  end  of  the  visit,  cardiologists  recorded  any  change  in
he  antihypertensive  treatment  regimen  (i.e.  an  increase  in
osage  of  the  same  drug,  a  change  of  drug  within  the  same
lass,  a  change  of  class  or  the  discontinuation  of  one  or  more
rugs).
GCVR  was  classiﬁed  according  to  French  guidelines  as
ow,  medium  or  high  based  on  BP  and  other  CVRFs.
tatistical analysis
he  results  of  statistical  analyses  are  presented  as  mean  and
tandard  deviation  values  for  quantitative  variables  and  as
requencies  for  qualitative  variables.  Signiﬁcance  was  esti-
ated  using  the  appropriate  test  (Wilcoxon  for  quantitative
nd  chi-square  for  qualitative  variables)  with  a  conﬁdence
evel  of  5%.
Two  multivariable  analyses  —one  in  patients  at  medium
CVR  and  one  in  patients  at  high  GCVR  —  were  carried  out
o  identify  factors  that  independently  correlated  with  the
rescription  of  any  test  designed  to  investigate  myocardial
schaemia  (exercise  testing  together  with  stress  echocar-
iography,  magnetic  resonance  imaging  or  scintigraphy),
ollectively  referred  to  as  ‘‘pooled  tests’’.
All  statistical  analyses  were  performed  using  SAS  8.2  soft-
are  (SAS  Institute,  Cary,  NC,  USA).
esults
etween  March  and  August  2010,  654  ofﬁce-based  cardi-
logists  throughout  France  participated  in  the  study.  The
hysicians  had  a  mean  of  18.8  years  of  experience  (median:
0  years).  Out  of  a  total  of  3456  patients  initially  included,
6  were  excluded  from  analysis  because  of  missing  key
ata  (BP  measurements  in  most  cases).  Thus,  the  analysed
opulation  consisted  of  3440  hypertensive  patients.  Base-
ine  social,  demographic  and  clinical  data  are  presented  for
his  population  as  a  whole  and  broken  down  according  to
ender  (53%  men,  47%  women)  (Table  1).  Compared  with
he  female  subpopulation,  the  mean  age  of  the  men  was
ower  (because  of  a  higher  proportion  of  women  aged  over
5  years),  with  a  higher  body  mass  Index  (BMI)  and  a  higher
requency  of  presence  of  three  or  more  CVRFs.  In  addition,
ore  of  the  men  were  heavy  drinkers  (18%  of  men,  3%
f  women)  and  had  end-organ  damage  (essentially  left
entricular  hypertrophy  as  measured  by  electrocardiogra-
hy  and  echocardiography),  documented  CVD  (myocardial
nfarction,  coronary  heart  failure,  aortic  aneurysm  or
issection  and  peripheral  atherosclerosis)  or  kidney  failure
Table  1).
The  proportion  of  both  genders  in  the  high-GCVR
ategory  was  high,  accounting  for  over  two-thirds  of  all
he  patients,  but  it  was  higher  in  men  (75%  of  men,  62%
f  women;  P  <  0.001)  due  to  higher  rates  of  diabetes,
yslipidaemia  and  smoking.
There  were  no  signiﬁcant  BP  differences  between
en  and  women  (mean  SBP/DBP  ±  standard  deviation:
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Table  1  Baseline  social,  demographic  and  clinical  data.
Men  (n  =  1819)  Women  (n  =  1621)  Total  (n  =  3440)  P
Data  Missing
data  (n)
Data  Missing
data  (n)
Data  Missing
data  (n)
Social  and  demographic
data
Age  (years)  64.60  ±  11.62  2  67.30  ±  12.18  2  65.80  ±  11.96  2  <  0.001a
Age  classes  (years)
< 50  184  (10.1)  138  (8.5)  322  (9.4)
50—65  694  (38.2)  485  (30.0)  1179  (34.3)
65—75  549  (30.2)  493  (30.5)  1042  (30.3)
≥  75  390  (21.5)  503  (31.1)  893  (26.0)  <  0.001b
BMI  (kg/m2)  28.00  ±  4.11  9  27.00  ±  5.04  14  27.50  ±  4.60  23  <  0.001a
BMI  classes  (kg/m2)
<  25  413  (22.8)  625  (38.9)  1038  (30.4)
25—30  930  (51.4)  591  (36.8)  1521  (44.5)
≥  30  467  (25.8)  391  (24.3)  858  (25.1)  <  0.001b
GCVR
Low  20  (1.1)  81  (5.0)  101  (2.0)
Medium  441  (24.2)  528  (32.6)  969  (28.2)
High  1358  (74.7)  1012  (62.4)  2370  (68.9)  <  0.001b
CVRFs
Age  >  50  (men)  or  >  60
(women)
1600 (88.1)  2  1170  (72.3)  2  2770  (80.6)  4  <  0.001b
Family  history  of  CV
events
400 (23.5) 116 317  (20.9) 104  717  (22.3)  220  0.078
Diabetes  (treated  or
untreated)
538 (29.7) 8  406  (25.2)  10  944  (27.6)  18  0.003b
High  cholesterolc 1173  (65.6) 27 933  (58.2) 18  2106  (62.0)  45  <  0.001b
Smoker 442  (24.5) 15  188  (11.7)  15  630  (18.5)  30  <  0.001b
Number  of  risk
factors
0 44  (2.4)  144  (8.9)  188  (5.5)
1  or  2  1040  (57.2)  1042  (64.3)  2082  (60.5)
≥  3  735  (40.4)  435  (26.8)  1170  (34.0)  <  0.001b
Other  relevant
conditions
Abdominal  obesity  799  (44.4)  1  672  (41.9)  18  1471  (43.3)  39  0.139b
Sedentary  lifestyle  1090  (60.1)  5  1131  (70.1)  8  2221  (64.8)  13  <  0.001b
Excessive  alcohol
consumption
314 (17.8)  53  42  (2.6)  21  356  (10.6)  74  <  0.001b
End-organ  involvement
At least  one  organ  741  (40.7)  538  (33.2)  1279  (37.2)  <  0.001b
Left  ventricular
hypertrophy
669  (37.2)  21  452  (28.4)  30  1121  (33.1)  51  <  0.001b
Microalbuminuria  199  (15.4)  527  162  (14.8)  526  361  (15.1)  1053  0.680b
CV  and  kidney  disease
At  least  one  CV  or
kidney  disease
739 (40.6)  453  (27.9)  1192  (34.7)  <  0.001b
Kidney  failure
(GFR  <  60  mL/minute)
or  protein-
uria  >  500  mg/day
157  (8.9)  56  142  (9.0)  45  299  (9.0)  101  0.916b
TIA  or  stroke  147  (8.1)  8  139  (8.6)  8  286  (8.4)  16  0.597bMI  196  (10.8)  12  64  (4.0)  9  260  (7.6)  21  <  0.001b
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Table  1  (Continued)
Men  (n  =  1819)  Women  (n  =  1621)  Total  (n  =  3440)  P
Data  Missing
data  (n)
Data  Missing
data  (n)
Data  Missing
data  (n)
Coronary  heart
failure  (without  MI)
248  (13.8)  18  144  (8.9)  11  392  (11.5)  29  < 0.001b
Peripheral
atherosclerosis
261  (14.6)  29  85  (5.3)  17  346  (10.2)  46  < 0.001b
Aortic  aneurysm  or
dissection
77  (4.3)  37  20  (1.3)  28  97  (2.9)  65  < 0.001b
Data are mean ± standard deviation or number (%). BMI: body mass index; CV: cardiovascular; CVRF: cardiovascular risk factor; GCVR:
global cardiovascular risk; GFR: glomerular ﬁltration rate; MI: myocardial infarction; TIA: transient ischaemic attack.
a Wilcoxon test.
b Chi-square test.
c Low-density lipoprotein cholesterol ≥ 1.6 g/L (4.1 mmol/L), high-density lipoprotein cholesterol ≤ 0.40 g/L (1 mmol/L).
h
s
(
v
t
C146/84  ±  17/10  mmHg  for  men,  147/84  ±  18/11  mmHg  for
women).
Hypertension  was  controlled  in  less  than  one-quarter
of  both  groups  (Table  2)  and  uncontrolled  in  over  92%  of
patients  with  diabetes  or  kidney  failure,  with  no  difference
according  to  gender  (92.0%  in  men  and  92.9%  in  women;
P  =  0.84).No  major  differences  according  to  gender  were  observed
regarding  drug  regimens,  with  three-quarters  of  patients
using  two  drugs  or  more  and  over  one-third  receiving  at  least
three  different  drugs.
o
o
p
Table  2  Blood  pressure  and  hypertension.
Men  (n  =  1819
SBP  (mmHg)  146.00  ±  16.8
DBP  (mmHg) 84.20  ±  10.29
BP  grade
BP <  140/90  mmHg  574  (31.6)  
140  ≤  SBP  <  160  and  90  ≤  DBP  <  100  mmHg  744  (40.9)  
160  ≤  SBP  <  180  and  100  ≤  DBP  <  110  mmHg  414  (22.8)  
BP  ≥  180/110  mmHg  87  (4.8)  
HT  history  (years)c 10.10  ±  7.90  
HT  ﬁrst  diagnosed  in  the  last  year  39  (2.2)  
HT  controlledd 438  (24.1)  
Number  of  antihypertensive  drugs
0  16  (0.9)  
1  457  (25.1)  
2 627  (34.5)  
≥  3 719 (39.5)
Data are mean ± standard deviation or number (%). BP: blood pressur
blood pressure.
a Wilcoxon test.
b Chi-square test.
c Missing data: men (n = 37); women (n = 33); total (n = 70).
d HT controlled if BP < 140/90 mmHg (or 130/80 mmHg in patients withAt  the  end  of  the  visit,  cardiologists  modiﬁed  the  anti-
ypertensive  treatment  in  over  50%  of  patients,  with  no
igniﬁcant  difference  emerging  between  men  and  women
52.7%  for  men  vs  54.8%  for  women;  P  =  0.21  [Fig.  1A]).  Con-
ersely,  the  higher  the  BP,  the  greater  the  likelihood  of  the
reatment  being  changed,  regardless  of  GCVR  (Fig.  1B  and
).  Most  of  the  changes  consisted  of  a  switch  to  another  class
f  drug  (41.0%  of  all  changes)  and/or  the  addition  of  at  least
ne  drug  (46.7%  of  changes)  (Fig.  2).
An  analysis  of  additional  cardiovascular  investigations
erformed  in  the  6  months  prior  to  the  visit  revealed  marked
) Women  (n  =  1621)  Total  (n  =  344)  P
3  147.20  ±  17.83  146.60  ±  17.31  0.052a
 83.50  ±  10.61  83.80  ±  10.45  0.051a
522  (32.2)  1096  (31.9)
597  (36.8)  1341  (39.0)
409  (25.2)  823  (23.9)
93  (5.7)  180  (5.2)  0.059b
11.00  ±  8.50  10.50  ±  8.20  0.012a
49  (3.1)  88  (2.6)  0.003b
401  (24.7)  839  (24.4)  0.653b
20  (1.2)  36  (1.0)
412  (25.4)  869  (25.3)
607  (37.4)  1234  (35.9)
582  (35.9)  1301  (37.8)
e; DBP: diastolic blood pressure; HT: hypertension; SBP: systolic
 diabetes or kidney failure).
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Figure 1. Treatment change after the consultation. A. Population
as a whole (n = 3440). B. Subpopulation of patients with uncontrolled
blood pressure (n = 2601). C. Population as a whole according to
blood pressure range. GCVR: global cardiovascular risk.
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ifferences  between  men  and  women  (Table  3).  Exercise
tress  tests  had  been  performed  more  than  twice  as  often
n  men  as  in  women  (40.7%  vs  18.8%;  P  < 0.001).  When  all
eans  of  investigating  myocardial  ischaemia  (i.e.  ‘pooled
ests’)  were  considered,  44.2%  of  the  men  had  a  further
nvestigation  compared  with  22.6%  of  the  women  (P  <  0.001).
imilar  gender-related  differences  were  seen  when  this
ariable  was  analysed  according  to  GCVR  sub-population
Table  3).  Moreover,  tests  to  investigate  sleep  apnoea  (17%
n  men,  8%  in  women;  P  <  0.001)  and  vascular  Doppler
ltrasonography  (43%  in  men,  37%  in  women;  P  <  0.001)
ere  all  prescribed  less  frequently  in  women  than  men.
After  adjustment  for  the  appropriate  variables  (age,
MI,  hypertension  duration,  smoking  status,  inactivity,
lcohol  consumption  and  aortic  aneurysm  or  dissection
or  medium  GCVR;  age,  BMI,  severity  of  hypertension,
ypertension  duration,  family  history  of  premature  cardio-
ascular  events,  diabetes,  dyslipidaemia,  smoking  status,
nactivity,  alcohol  consumption,  kidney  failure,  transient
schaemic  attack/stroke,  myocardial  infarction,  coronary
eart  failure  and  peripheral  atherosclerosis  for  high  GCVR)
he  chance  of  having  a  ‘pooled  test’  remained  higher  in  men
han  in  women  in  both  the  medium-GCVR  and  high-GCVR
roups  (odds  ratio  2.49,  95%  conﬁdence  interval  1.78—3.49,
 <  0.001  and  odds  ratio  1.94,  95%  conﬁdence  interval
.58—2.40,  P  <  0.001,  respectively).
The  other  factors  associated  with  prescription  of  a
‘pooled  test’’  were  age  and  smoking  in  the  medium-GCVR
opulation,  and  a  family  history  of  cardiovascular  events,  a
istory  of  myocardial  infarction  or  coronary  artery  disease,
ge,  diabetes,  high  cholesterol,  moderate  hypertension  and
moking  in  the  high-GCVR  population  (Fig.  3A—D).
iscussion
he  primary  objective  of  the  PARITE  study  was  to  assess
he  therapeutic  decision  resulting  from  a  single  study  visit.
omplementary  cardiovascular  investigations  performed  in
he  6  months  before  the  study  visit  were  recorded  as  such  in
he  database  and  analysed.  Complementary  cardiovascular
nvestigations  prescribed  or  performed  at  the  study  visit
ere  not  addressed.
The  main  ﬁnding  of  the  PARITE  study  was  that  the  decision
o  modify  BP  treatment  in  a  representative  population  of
ypertensive  patients  referred  to  an  ofﬁce-based  cardiolo-
ist  was  not  related  to  gender.  In  patients  with  uncontrolled
ypertension,  the  treatment  regimen  was  changed  regard-
ess  of  GCVR  class.  The  treatment  regimen  was  modiﬁed
n:  90%  of  uncontrolled  patients  when  SBP  is  greater  than
r  equal  to  160  mmHg  and/or  DBP  is  greater  than  or  equal
o  100  mmHg;  60%  of  moderately  uncontrolled  patients
140—160/90—100  mmHg);  and  only  10%  of  controlled
atients  (<  140/90  mmHg).  However,  the  data  collected
egarding  the  cardiologist’s  decisions  only  concerned  treat-
ent  modiﬁcation  at  the  visit  itself  and  ignored  any  other
easures  that  may  have  been  implemented  afterwards,uch  as  ambulatory  24-hour  BP  monitoring,  a  procedure
o  investigate  renal  artery  stenosis  or  a  diagnosis  of  sleep
pnoea.  Thus,  any  measure  undertaken  to  obtain  informa-
ion  in  order  to  decide  on  treatment  strategy  at  a  later
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Figure 2. Nature of changes in treatment at the end of the consultation.
Table  3  Complementary  examinations  performed  in  the  preceding  6  months.
Men  Women  Total  Pa
n  (%)  Missing
data  (n)
n  (%)  Missing
data  (n)
n  (%)  Missing
data  (n)
Pooled  stress  testb
Total  populationc 800  (44.2)  8  363  (22.6)  14  1163  (34.0)  22  <  0.001
High-risk  populationd 663  (49.1)  8  271  (26.9)  6  934  (39.6)  14  <  0.001
Patients  with  no  history  of  CHDe 491  (35.9)  7  265  (18.9)  14  756  (27.3)  21  <  0.001
Investigation  of  sleep  apnoea
Total  populationc 308  (17.1)  21  131  (8.2)  23  439  (12.9)  44  <  0.001
High-risk  populationd 272  (20.3)  17  102  (10.3)  18  374  (16.0)  35  <  0.001
Vascular  Doppler  ultrasonography
Total  populationc 776  (43.2)  22  593  (36.9)  16  1369  (40.2)  38  <  0.001
High-risk  populationd 676  (50.4)  18  471  (47.0)  9  1147  (49.0)  27  0.095
Standard  or  transoesophageal  echocardiography
Total  populationc 1201  (66.5)  12  1061  (65.8)  9  2262  (66.2)  21  0.691
High-risk  populationd 953  (70.6)  9  732  (72.6)  4  1685  (71.5)  13  0.294
Ambulatory  BP  monitoring
Total  populationc 642  (35.6)  14  596  (37.0)  12  1238  (36.3)  26  0.271
High-risk  populationd 464  (34.5)  13  370  (36.8)  7  834  (35.5)  20  0.245
Ambulatory  ECG
Total  populationc 260  (14.4)  19  220  (13.7)  17  480  (14.1)  36  0.542
High-risk  populationd 218  (16.3)  18  154  (15.4)  10  372  (15.9)  28  0.556
BP: blood pressure; CHD: coronary heart disease; ECG: electrocardiography.
a Chi-square test.
b Exercise testing + stress echocardiography/magnetic resonance imaging/scintigraphy.
c n = 1819 men + 1621 women = 3440.
d n = 1358 men + 1012 women = 2370.
e n = 1375 men + 1413 women = 2788.
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Figure 3. Factors that determined whether or not a ‘‘pooled test’’ was ordered (logistic regression). A. A pooled test in patients at high
global cardiovascular risk. B. A pooled test in patients at medium global cardiovascular risk. C. A sleep apnoea test in patients at high global
c
c
ardiovascular risk. D. A sleep apnoea test in patients at medium global c
oronary heart disease; CV: cardiovascular; LVHT: left ventricular hypertardiovascular risk. BMI: body mass index; BP: blood pressure; CHD:
rophy; M: men; W: women.
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date  —  with  temporary  deferral  of  the  actual  therapeutic
decision  —  would  appear  in  the  results  as  inertia.
The  population  in  the  present  study  was  at  high  risk  of
cardiovascular  events.  Compared  with  a  global  population
treated  by  general  practitioners  described  in  the  ENNS  sur-
vey,  where  50.9%  of  the  patients  were  controlled  (58.5%  of
women  vs  41.8%  of  men;  P  =  0.01)  [15], three-quarters  of
the  patients  in  our  study  were  uncontrolled  despite  over
one-third  of  them  being  on  three  or  more  antihyperten-
sive  drugs.  In  the  MONA  LISA  survey  of  hypertensive  patients
[16],  62%  of  women  and  77.9%  of  men  were  controlled  (i.e.
BP  <  140/90  mmHg).
Our  results  are,  however,  consistent  with  those  of  the
International  Database  on  Ambulatory  Blood  Pressure  in  rela-
tion  to  Cardiovascular  Outcomes  (IDACO  registry)  [17]. In
this  survey  of  9357  patients  from  11  countries,  69.7%  of
hypertensive  women  and  71.7%  of  the  men  were  under-
treated  or  uncontrolled  at  inclusion.  In  the  PHENOMEN
study  [18], conducted  with  general  practitioners,  52%  of
uncontrolled  hypertensive  patients  were  at  high  GCVR  com-
pared  with  72%  in  the  cardiologist-referred  population  of  the
PARITE  study.
A gender  difference  with  regard  to  investigations  was
observed  in  our  study,  with  fewer  tests  having  been  per-
formed  to  explore  myocardial  ischaemia  in  women  than  in
men  in  the  6  months  prior  to  study  visit.  This  was  the  case
even  among  those  patients  with  no  prior  history  of  coronary
disease.  A  similar  gender  difference  was  observed  for  car-
diovascular  Doppler  ultrasonography.  These  gender-related
differences  in  CVD  management  are  consistent  with  ﬁnd-
ings  of  previous  studies  [19,20]  and  remain  unexplained.  For
example,  one  study  showed  that,  after  a  stroke,  women
have  signiﬁcantly  fewer  cerebral  imaging,  Doppler  and
echocardiography  examinations  [15]. In  another  study,  on
patients  with  ST-segment  elevation  myocardial  infarction
acute  coronary  syndrome,  it  was  shown  that  women  aged
over  65  years  are  less  likely  to  undergo  percutaneous  coro-
nary  intervention  than  other  patients  [2].
Finally,  a  meta-analysis  of  clinical  trials  performed  in
heart  failure  showed  that  only  16  to  23%  of  women  were
implanted  with  a  cardioverter  deﬁbrillator  [1].  Surpris-
ingly  in  this  study  with  a  high  percentage  of  uncontrolled
hypertensive  patients,  few  sleep  apnoea  tests  had  been
performed  at  all  and  even  fewer  in  women.  Similarly,  ambu-
latory  BP  monitoring  had  not  been  ordered  in  many  cases,
although  no  gender-related  difference  was  observed  in  this
respect.
Limitations
There  are  two  main  limitations  of  this  study,  above  and
beyond  its  cross-sectional  design  and  the  lack  of  informa-
tion  regarding  diagnostic  investigations  at  the  study  visit
that  may  misleadingly  point  to  treatment  inertia.  The  ﬁrst
limitation  is  that  it  was  a  high-risk  study  population  of
patients  referred  to  a  cardiologist.  The  results  should  there-
fore  be  analysed  cautiously  as  they  may  not  reﬂect  the
global  hypertensive  population.  The  second  limitation  is  that
the  participating  cardiologists  were  aware  that  one  of  the
purposes  of  the  study  was  to  analyse  gender-related  dif-
ferences  in  the  management  of  hypertension.  This  could
therefore  have  introduced  a  bias  in  the  decision-making279
rocess  although  the  fact  that  a  gender-related  difference
as  actually  detected  suggests  that  any  such  bias  was  at
east  mitigated.
onclusions
his  study  shows  that  in  French,  ofﬁce-based,  cardiol-
gy  practice,  the  antihypertensive  regimen  is  prescribed
ithout  taking  gender  into  account.  However,  the  lower
requency  of  cardiovascular  tests  prescribed  for  women
onﬁrms  that  there  is  room  for  improvement  in  the  investi-
ation  of  CVD  in  women.  Encouraging  healthcare  providers
o  familiarize  themselves  with  and  implement  the  speciﬁc
uidelines  available  is  crucial  for  improving  cardiovascular
anagement  in  women.
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